Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Other Operating Expenses (2016 - 2026)

Collegium Pharmaceutical has reported Other Operating Expenses over the past 6 years, most recently at -$19000.0 for Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 99.96% year-over-year to -$19000.0; the TTM value through Dec 2025 reached -$35.2 million, up 43.99%, while the annual FY2025 figure was -$5.4 million, 66.05% up from the prior year.
  • Other Operating Expenses for Q4 2025 was -$19000.0 at Collegium Pharmaceutical, up from -$10.9 million in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $11.6 million in Q3 2023 and troughed at -$207.0 million in Q4 2023.
  • A 3-year average of -$29.3 million and a median of -$9.4 million in 2024 define the central range for Other Operating Expenses.
  • On a YoY basis, Other Operating Expenses climbed as much as 99.96% in 2025 and fell as far as 302.67% in 2025.
  • Year by year, Other Operating Expenses stood at -$207.0 million in 2023, then skyrocketed by 74.99% to -$51.8 million in 2024, then surged by 99.96% to -$19000.0 in 2025.
  • Business Quant data shows Other Operating Expenses for COLL at -$19000.0 in Q4 2025, -$10.9 million in Q3 2025, and -$10.2 million in Q2 2025.